TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Social influence on physical activity
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Changes in labs and vitals relative to disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-meters' walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: no evidence of disease activity (NEDA-3) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arch Height Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: exercise capacity change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute incidence of thromboembolic event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Delta SOFA (ΔSOFA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-rated device acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient-rated device comfort
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Patient-rated device ease of use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 1-year local control rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score on Beck Depression Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Abnormal heart rhythms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pharmacokinetics of DA-7503
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of subjects with vIGA-AD score of clear or almost clear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gain in stretched penile length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: measurement of tissue stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: measurement of passive muscle tone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: measurement of creep of tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: measurement of the range of shoulder joint motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Duration till 1st requirement of analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Hamilton Depression Rating Scale (HAMD) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Length of Time Until Surgical Indication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence rate, characteristics, and severity of adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Shift from baseline of vital sign
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Appetite
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bioimpendance Analysis Result
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Functional outcome assessment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of target tumors completely ablated in one procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Frequency of adverse events post-laser ablation and post-surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Comprehensive positive score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pathological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change from maximum transverse tumor diameter after neoadjuvant therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Inclusion Rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Completion Ratio of protocols
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Wound healing area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: 24-hour urine protein quantification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lean weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of rabeprazole
Endpoint domain: Adverse events/effects
Primary endpoint: Gastrointestinal appetite hormones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Immunephenotyping of human PBMC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Operative time for colpotomy and vaginal cuff closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Depressive Symptom Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of residual adenomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: invasive disease free survival (iDFS)
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of Addison's disease
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of Alopecia areata
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of Autoimmune hemolytic anemia
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of Arteriitis temporalis
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of Graves' disease
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of ankylosing spondylitis
Endpoint domain: Mortality/survival
Primary endpoint: Berg Balance scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time up and Go
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composition of the digestive bacterial microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Treatable traits distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants with solicited adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Seroconversion rate of neutralizing antibodies against Sabin and wild-type poliovirus type 1, 2, and 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Generalized anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Diagnostic performance of radiographers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of NTP42:KVA4
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in QT interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sessions' acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Program acceptability, appropriateness, and feasibility
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Recruitment, retention, and attendance rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Safety/unexpected events
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment Fidelity Check
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change from baseline of omega-3 index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total postoperative consumption of rescue analgesics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average tumour dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Plasma elimination half-life (t1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PI value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in skin microbiome taxonomic units
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reversal of cardio-metabolic abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Residual renal function of donors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Graft kidney function of recipient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Quantification of HBV DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantification of HBV markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v5.0
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve (AUC) of HTS and TFV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Marginal bone level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Area under the plasma concentration-time curve from zero to the last quantifiable concentration (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from zero to infinity (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adrenocortical insufficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Incidence of serious surgery-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in muscle oxidative stress via glutathione reductase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in blood oxidative stress via glutathione reductase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time In Range (TIR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: BP screening coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical attachment level reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proficiency in Crown Preparation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Students' perception about demonstration techniques
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percent of patients with quantifiable 64Cu-DOTA-trastuzumab PET uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comparison of average min SUVmax values in responders versus non-responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak value for SLH distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leg symmetry index for SLH (LSISLH distance)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Code Status De-escalation
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With ANNE Sensor Related Adverse Skin Sensitivity Events
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in Father Involvement
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Changes in father's Coparenting
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: prevalence of infection by MDRO
Endpoint domain: Adverse events/effects
Primary endpoint: Composite efficacy endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in maximal isometric knee-extension force of the right leg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in anteroposterior thickness of the right patellar tendon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in neovascularization of the right patellar tendon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Postoperative arm volume measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle size, lower extremities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Scores of hospice care status
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Absolute change in terminal thread density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in HIV testing frequency
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: HIV status knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prevalence of infectious diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Success of diagnostic device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of PET/MR in preoperative endometriosis detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction to a PedMIDAS score of 20 or less
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-Procedure Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Presence of clinical arrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of participants with Angina
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Death during the first week
Endpoint domain: Mortality/survival
Primary endpoint: Change in the Behavioural Approach Test (BAT)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Acrophobia Questionnaire (AQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in Heart Rate Variability (HRV) during the BAT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of retinal fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and Tolerability of ONL1204
Endpoint domain: Adverse events/effects
Primary endpoint: Columbia-Suicide Severity Rating Scale - Intensity of Ideation Sub-scale Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Beck Scale for Suicidal Ideation Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of skin damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Correlation coefficient of Willems method
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation coefficient of London Atlas method
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation coefficient of Cameriere European formula
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of time wearing device
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: FACIT TS-G Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Time to disease progression of irradiated lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Concordance of HPV-16 genotype results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of defactinib in glioblastoma and brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of avutometinib (VS-6766) in glioblastoma and brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of adverse events associated with defactinib
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of adverse events associated with VS-6766
Endpoint domain: Adverse events/effects
Primary endpoint: Academic self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Rate of combined major and minor bleeding events
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Mini Mental State Examination after treatment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Presence of blisters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Changes in blood fatty acid composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Erythropoietin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: hepcidin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pain assessed by visual analog scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total number of treatment days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Podocyte integrity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Satisfaction with Decision scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Knowledge on vestibular schwannoma management scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: quality of sexual life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Child age and sex adjusted body mass index z-score (BMIz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Child percentage of the 95th percentile BMI (%BMIp95)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Child Overeating episodes
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Prevalence of subclinical vertebral fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Compliance Scale
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adherence with the program
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pathologic response as defined by the residual cancer burden (RCB) index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Salival Cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Inspiration volume, mean change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Inspiration volume, repeated measures over 5 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Retention in treatment at 90 days
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Prevention of pneumococcal infections
Endpoint domain: Adverse events/effects
Primary endpoint: Immunogenicity of PCV13i
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 1-point IGA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-point IGA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NS Sign
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WI-NRS score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: TSQM
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rescue Therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Child Attitude Toward Illness Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of patients without grade 2 and more toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Safety and tolerability of IMGS-001
Endpoint domain: Adverse events/effects
Primary endpoint: Recommended Phase 2 dose (RP2D) of IMGS-001
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change From Baseline Diabetic Neuropathy Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline of the Foot and Ankle range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Diagnostic efficiency of ddPCR combined with transcriptomic analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prognostic value of ddPCR combined with transcriptomic analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility and acceptability of the program
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in pain levels assessed using the Numerical Pain Rating Scale (NPRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in functional Levels assessed using the WOMAC Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in lower limb muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes